title: Angiogenesis-targeted therapies in prostate cancer.
abstract: Most patients with metastatic prostate cancer will respond initially to ablation of gonadal androgen production. Eventually, all patients will develop progressive disease despite continued androgen suppression, a condition called androgen-independent or hormone-refractory prostate cancer. Hormone-refractory prostate cancer is characterized by virulent biologic and clinical behavior. Recently, docetaxel-based chemotherapy has been shown to improve survival and quality of life in this disease when compared with mitoxantrone-based therapy. However, results remain suboptimal. Recently, there have been remarkable advances in the delineation of the mechanisms of cancer growth, metastasis, and the intricate interactions between tumor cells and the surrounding normal tissues. The accumulated evidence has confirmed the importance of angiogenesis in these processes and validated the theory that inhibition of neovascularization is a promising therapeutic anticancer strategy. Currently, dozens of compounds that interfere with different steps of the angiogenic cascade are in preclinical and clinical development. Some of these agents have exhibited promising antitumor activity in hormone-refractory prostate cancer. This review summarizes the molecular mechanisms implicating angiogenesis in the development and progression of advanced-stage prostate cancer, as well as the drug development efforts that are targeting this process.
authors.affiliation: University of California Davis Cancer Center, 4501 X St, Suite 3016, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu
authors.forename: Primo N
authors.initials: PN
authors.lastname: Lara
authors.forename: Przemyslaw
authors.initials: P
authors.lastname: Twardowski
authors.forename: David I
authors.initials: DI
authors.lastname: Quinn
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D016232:Endothelins / Q000494:pharmacology / Q000502:physiology; D036342:Ephrins / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D008297:Male; D020782:Matrix Metalloproteinases / Q000494:pharmacology; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D036081:Receptors, Eph Family / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology
chemical_list: D020533:Angiogenesis Inhibitors; D018931:Antineoplastic Agents, Hormonal; D016232:Endothelins; D036342:Ephrins; D042461:Vascular Endothelial Growth Factor A; D036081:Receptors, Eph Family; D020782:Matrix Metalloproteinases